100 related articles for article (PubMed ID: 10743718)
1. Recent approaches in the treatment of Hodgkin's lymphoma.
Raida L
Acta Univ Palacki Olomuc Fac Med; 1999; 142():13-7. PubMed ID: 10743718
[TBL] [Abstract][Full Text] [Related]
2. [Hodgkin's lymphoma: problems in the treatment of the early stages].
Bacigalupo A; Barra S; Corvò R; Guenzi M; Scolaro T; Vitale V
Radiol Med; 1996 Nov; 92(5):620-3. PubMed ID: 9036456
[TBL] [Abstract][Full Text] [Related]
3. [Clinical aspects and primary therapy of Hodgkin's lymphomas].
Sieber M; Tesch H; Diehl V
Praxis (Bern 1994); 1996 Mar; 85(12):364-70. PubMed ID: 8643899
[TBL] [Abstract][Full Text] [Related]
4. Autologous stem cell transplantation (ASCT) in Hodgkin's disease: present status.
Angelo M; Carella AM
Pathol Biol (Paris); 1993 Jan; 41(1):107-9. PubMed ID: 7686282
[No Abstract] [Full Text] [Related]
5. [Therapy of the recurrence of malignant lymphoma].
Brockmann B
Z Arztl Fortbild (Jena); 1992 Sep; 86(17):843-6. PubMed ID: 1384247
[No Abstract] [Full Text] [Related]
6. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
[TBL] [Abstract][Full Text] [Related]
7. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
[TBL] [Abstract][Full Text] [Related]
8. [Primary treatment of advanced Hodgkin's disease].
Illés A; Udvardy M; Molnár Z
Orv Hetil; 2005 Jan; 146(5):195-202. PubMed ID: 15773586
[TBL] [Abstract][Full Text] [Related]
9. [Malignant lymphomas--a showpiece?].
Obrecht JP
Schweiz Med Wochenschr; 1983 Sep; 113(36):1279-84. PubMed ID: 6635627
[TBL] [Abstract][Full Text] [Related]
10. Radiotherapy for early-stage Hodgkin's lymphoma: a 21st century perspective and review of multiple randomized clinical trials.
Bar Ad V; Paltiel O; Glatstein E
Int J Radiat Oncol Biol Phys; 2008 Dec; 72(5):1472-9. PubMed ID: 19028275
[TBL] [Abstract][Full Text] [Related]
11. New strategies for the treatment of early stages of Hodgkin's lymphoma.
Macdonald DA; Connors JM
Hematol Oncol Clin North Am; 2007 Oct; 21(5):871-80. PubMed ID: 17908625
[TBL] [Abstract][Full Text] [Related]
12. First-line treatment of Hodgkin's lymphoma.
Klimm B; Engert A; Diehl V
Curr Hematol Rep; 2005 Jan; 4(1):15-22. PubMed ID: 15610655
[TBL] [Abstract][Full Text] [Related]
13. Personalized immunotherapy for the treatment of non-Hodgkin's lymphoma: a promising approach.
Vose JM
Hematol Oncol; 2006 Jun; 24(2):47-55. PubMed ID: 16447298
[TBL] [Abstract][Full Text] [Related]
14. Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials.
Shimabukuro-Vornhagen A; Haverkamp H; Engert A; Balleisen L; Majunke P; Heil G; Eich HT; Stein H; Diehl V; Josting A
J Clin Oncol; 2005 Aug; 23(24):5739-45. PubMed ID: 16009944
[TBL] [Abstract][Full Text] [Related]
15. Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?
Diehl V; Fuchs M;
Transfus Apher Sci; 2007 Aug; 37(1):37-41. PubMed ID: 17714996
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
Dawson LA; Saito NG; Ratanatharathorn V; Uberti JP; Adams PT; Ayash LJ; Reynolds CM; Silver SM; Schipper MJ; Lichter AS; Eisbruch A
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):208-18. PubMed ID: 15093918
[TBL] [Abstract][Full Text] [Related]
17. [Medicinal therapy of malignant lymphomas].
Aul C; Schroeder M; Giagounidis A
Radiologe; 2002 Dec; 42(12):943-53. PubMed ID: 12486548
[TBL] [Abstract][Full Text] [Related]
18. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma.
Martin WG; Ristow KM; Habermann TM; Colgan JP; Witzig TE; Ansell SM
J Clin Oncol; 2005 Oct; 23(30):7614-20. PubMed ID: 16186594
[TBL] [Abstract][Full Text] [Related]
19. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
Wong SF; Chan HO
Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
[TBL] [Abstract][Full Text] [Related]
20. Combined modality treatment of Hodgkin's lymphoma.
Klimm B; Engert A
Cancer J; 2009; 15(2):143-9. PubMed ID: 19390310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
